Accessibility Menu
Ndt Pharmaceuticals logo

Ndt Pharmaceuticals(OTC) NDTP

Market Cap$87.68MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2011)-99%
5 Year+547,900%
1 Year+798%
1 Month+19%
$0.55
-0.36%
-0.00Today
Ndt Pharmaceuticals last closing stock price
MetricPriceDate
Last closeUSD 0.552026-08-04
Ndt Pharmaceuticals stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-0.36%USD 0.552026-07-28
1 month+19.28%USD 0.462026-07-01
3 month-5.53%USD 0.582026-05-06
Year to date-69.39%USD 1.792025-12-31
1 year+798.36%USD 0.062025-08-04
3 year+1,752.6%USD 0.032023-08-02
5 year+547,900%USD 0.002021-08-05
Since inception-99.16%USD 65.002011-10-21

Ndt Pharmaceuticals Financials at a Glance

Market Cap

$87.68MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$122.34K

Net Income (TTM)

-$307.84K

EPS (TTM)

-$0.00

P/E Ratio

-342.50

Dividend

$0.00

Beta (Volatility)

173.00 (High)

Price

$0.55

Volume

200

Open

$0.55

Previous Close

$0.55

Daily Range

$0.55 - $0.55

52-Week Range

$0.05 - $2.10

Estimated Earnings Date

Nov 14, 2007

NDTP News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Ndt Pharmaceuticals

NDT Pharmaceuticals Inc. is a biotechnology firm based in Vienna, Virginia, focused on developing treatments for serious neurological conditions, particularly those resulting from traumatic brain injuries. The company aims to address significant unmet medical needs in the healthcare sector.

Products and Services
  • Innovative therapies targeting neurological disorders
  • Research and development in traumatic brain injury treatments
  • Collaboration with healthcare professionals for clinical trials
Growth Outlook
  • Potential market expansion in the neurological treatment sector
  • Increased focus on research and development initiatives
  • Strategic partnerships may enhance product pipeline
Financial Highlights
  • Recent quarterly net income of -$7,568, indicating ongoing investment in R&D
  • Trailing twelve months (TTM) cash and short-term investments of $1,650
  • Current liabilities of $98,343, reflecting operational commitments
NDT Pharmaceuticals Inc. operates in a niche market with significant growth potential, particularly in the treatment of neurological disorders. The company's focus on research and development is evident in its financials, with substantial investments aimed at advancing its product offerings. Despite reporting a net loss in recent quarters, the commitment to innovation and potential market expansion positions the company for future growth. The current financial landscape, including cash reserves and liabilities, reflects the ongoing operational strategy to develop effective treatments for serious medical conditions.
AI Generated • Jul 8, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

13

CEO

Joseph C. Passalaqua

Website

www.ndtpharma.com

Headquarters

Vienna, VA 22182, US

NDTP Financials

Key Financial Metrics (TTM)

Gross Margin

-32.44%

Operating Margin

-248.67%

Net Income Margin

-251.62%

Return on Equity

-3.08%

Return on Capital

-49.46%

Return on Assets

-0.75%

Earnings Yield

-0.29%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$87.68MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

160.00M

Volume

200

Avg. Volume

1.62K

Financials (TTM)

Gross Profit

-$39.69K

Operating Income

-$304.22K

EBITDA

-$304.22K

Operating Cash Flow

-$11.20K

Capital Expenditure

$3.00

Free Cash Flow

-$11.20K

Cash & ST Invst.

$10.85K

Total Debt

$701.00K

Ndt Pharmaceuticals Performance Analysis

Ndt Pharmaceuticals annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Ndt Pharmaceuticals sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Ndt Pharmaceuticals annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-12-31USD -0.00N/A
20242024-12-31USD -0.00-80.0%
20252025-12-31USD -0.00100.0%
Ndt Pharmaceuticals sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31-1600.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$122.34K

N/A

Gross Profit

-$39.69K

N/A

Gross Margin

-32.44%

N/A

Market Cap

$87.68MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

0

N/A

Net Income

-$288.05K

-9400.3%

EBITDA

-$284.43K

-9280.9%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$10.85K

+1577.3%

Total Debt

$701.00K

N/A

Accounts Receivable

$133.33K

N/A

Inventory

$1.50M

N/A

Long Term Debt

$701.00K

N/A

Short Term Debt

$0.00

N/A

Return on Assets

-0.75%

N/A

Return on Invested Capital

-0.75%

N/A

Free Cash Flow

-$190.00

+94.8%

Operating Cash Flow

-$193.00

+94.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
JWCTFJW (Cayman) Therapeutics Co. Ltd
$0.20+0.00%
AAWHAscend Wellness Holdings, Inc.
$0.41-0.59%
SCNLFScancell Holdings plc
$0.13+4.00%
MLLCFMolecular Partners AG
$3.80+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
SPCXSpace Exploration Technologies
$108.27-0.14%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$38.29+0.03%
TQQQProShares Trust - ProShares UltraPro Qqq
$72.84-0.03%
MUUDirexion Shares ETF Trust - Direxion Daily Mu Bull 2x Shares
$27.63+0.00%

Questions About NDTP

What is the current price of Ndt Pharmaceuticals?

Ndt Pharmaceuticals is trading at $0.55 per share.

What is the 52-week range for Ndt Pharmaceuticals?

Over the past 52 weeks, Ndt Pharmaceuticals has traded between $0.05 and $2.10.

How much debt does Ndt Pharmaceuticals have?

As of the most recent reporting period, Ndt Pharmaceuticals reported total debt of $701.00K.

How much cash does Ndt Pharmaceuticals have on hand?

Ndt Pharmaceuticals reported $10.85K in cash and cash equivalents in its most recent financial results.

What is Ndt Pharmaceuticals’s dividend yield?

Ndt Pharmaceuticals does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services